Targets › SELENOP
3 programs from 3 companies in 3 trials: 2 Phase 3, 1 Phase 2; Cardiovascular, Psychiatry; next expected readout Apr 2027.
Might be responsible for some of the extracellular antioxidant defense properties of selenium or might be involved in the transport of selenium. May supply selenium to tissues such as brain and testis. (UniProt, P49908)
Open in Phaseline: the race on SELENOP, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Tor Biering-Sørensen | Selenium Cofactor for selenoproteins including glutathione peroxidase; antioxidant support | SELENOP | Phase 3 | Heart Failure | Dec 2028 |
| Skane University Hospital | Selenium (Bio-SelenoPrecise) Selenium supplementation; trace element cofactor for selenoproteins involved in antioxidan | SELENOP, SELENOW | Phase 3 | Heart Failure | Mar 2030 |
| First Affiliated Hospital of Chongqing Medical University | selenium yeast supplementation selenium cofactor for selenoprotein synthesis | SELENOP, SELENOK, SELENOW, SELENOF | Phase 2 | Depression - Major Depressive Disorder | Apr 2027 |
Heart Failure (2) Depression - Major Depressive Disorder (1)
small molecule (1)
Skane University Hospital (1) Tor Biering-Sørensen (1) First Affiliated Hospital of Chongqing Medical University (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.